Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 89

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 89
---
-consuming, and the outcome is unpredictable. If trade secrets which are material to our business
were to be obtained by a competitor, our competitive position would be harmed.

We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

Although we try to ensure that
our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or
these employees have used or disclosed IP, including trade secrets or other proprietary information, of any such employee’s former
employer. In addition, while we typically require our employees, consultants and contractors who may be involved in the development of
IP to execute agreements assigning such IP to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
IP that we regard as our own, which may result in claims by or against us related to the ownership of such IP. We are not aware of
any threatened or pending claims that any of our projects involve misappropriated IP or other proprietary information, but in the future
litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable IP rights. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management.

<div align='center'>46</div>

We may be unable to execute on the optimal development plan for one or more of our existing product candidates if we are unable to obtain or maintain necessary rights for some aspect of the developing technology through acquisitions or licenses.

Our existing programs currently
use or may in the future use additional technologies subject to proprietary rights held by others, such as particular compositions or
methods of manufacture, treatment, or use. The licensing and acquisition of IP rights is a competitive area, and more established companies
may pursue strategies to license or acquire such IP rights that we may consider necessary or useful. These established companies may have
a competitive advantage over us due to their size, cash resources and greater capabilities in clinical development and commercialization.

In addition, companies that
perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire IP rights
on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain or maintain licenses
or other rights from other parties to use IP of those parties, our business, financial condition